Stock Screener App

Frei - Play StoreApp Store

Installieren Installieren

Dow:

Nasdaq:

S&P 500:

QGEN

$50.220.24%-0.12

Nachbörslich: 50.17-0.05 -0.10%

Qiagen Nv (QGEN)

Date: O: H: L: C: Vol:

Qiagen Nv Aktie (QGEN) Neueste Nachrichten

Thailand Next Generation Sequencing (NGS) Market Size, Share, Trends, and Forecast - 2026 to 2036 | Precision Medicine Drives 12.7% CAGR and a $305.21 Million Opportunity - GlobeNewswire Inc.

Qiagen (QGEN) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release - Zacks Investment Research

Halper Sadeh LLC is Investigating Whether QGEN, VCTR, RLYB are Obtaining Fair Deals for their Shareholders - GlobeNewswire Inc.

Qiagen N.V. : Deutsche Bank reaffirms its Buy rating - www.marketscreener.com

JPMorgan Downgrades Qiagen NV (QGEN) to Neutral - StreetInsider

Qiagen N.V. : Reduced to Neutral by JP Morgan - marketscreener.com

7 Firms Advise EQT, Qiagen On $12.1B Take-Private Deal - Law360

Qiagen Agrees to EUR10.8 Billion Takeover by EQT - marketscreener.com

QIAGEN reports preliminary Q3 2026 results - The National Law Review

EQT to buy molecular testing firm Qiagen for $10.8 billion - Reuters

EQT to Acquire Qiagen for About €9.6 Billion - Briefs Finance

QIAGEN and EQT Private Equity announce agreement on a recommended voluntary all-cash public takeover offer - Voice of Alexandria

QIAGEN and EQT Private Equity announce agreement on a recommended voluntary all-cash public takeover offer - Business Wire

QIAGEN N.V. (QIA) Agrees To €46.50/Share Cash Tender Offer From EQT - TradingView

QIAGEN N.V. (QIA) Agrees to €46.50/Share Takeover; Q3 Sales $548M, EPS $0.65 - TradingView

QIAGEN N.V.: Conclusion of a Business Combination Agreement with EQT Private Equity; preliminary Q3 2026 results and suspension of full-year 2026 outlook - TradingView

QIAGEN N.V. (QIA) Agrees to €46.50/Share EQT Tender; Suspends FY26 Outlook - TradingView

QIAGEN N.V. (QIA) Gets €46.50/Share Cash Takeover Offer Backed by EQT - TradingView

EQT Nears €9.6 Billion Deal for Molecular Testing Firm Qiagen - Bloomberg.com

Qiagen N.V. Stock 12‑Month Price Target Cut to $47.57, Implies 2% Upside - TradingView

Qiagen shares surge on report of advanced EQT takeover talks - Yahoo Finance

EQT Is in Advanced Talks to Buy Testing Firm Qiagen - Bloomberg.com

QIAGEN N.V. (NYSE:QGEN) Sets Up for a Technical Breakout - ChartMill

Saudi Arabia Non-Invasive Prenatal Testing Market 2026-2034: Executive Report | NGS Adoption and Healthcare Investment Drive 13.35% CAGR Toward US$162.16 Million - GlobeNewswire Inc.

Global Microbiology Testing Market to Grow Rapidly at a CAGR of ~9% by 2034 | DelveInsight - GlobeNewswire Inc.

QIAGEN N.V. (QIA): BlackRock Discloses 12.91% Voting Rights - TradingView

PTA-PVR: QIAGEN N.V.: Release according to Article 40, Section 1 of the WpHG - TradingView

QIAGEN N.V. (QIA) Notes AFM Filing on BlackRock Voting Rights - TradingView

QIAGEN N.V. (QIA) Notes AFM Disclosure on BlackRock Voting Rights - TradingView

Release according to Article 40, Section 1 of the WpHG - TradingView

Qiagen N.V. Stock 12‑Month Price Target Raised to $47.5, Implies 7% Upside - TradingView

Qiagen stock gains 0.39 percent after-hours to EUR 40.74 - AD HOC NEWS

Qiagen stock gets a new AI growth story from QIAGEN - AD HOC NEWS

QIAGEN Expands AI-Powered Bioinformatics for Research and Drug Discovery - BioSpace

QIAGEN N.V. (QIA) Notes AFM Disclosure on BlackRock Voting Rights - TradingView

QIAGEN N.V. (QIA): BlackRock Notifies 13.04% Voting Rights - TradingView

PTA-PVR: QIAGEN N.V.: Release according to Article 40, Section 1 of the WpHG - TradingView

Release according to Article 40, Section 1 of the WpHG - TradingView

QIAGEN N.V. (QIA) Receives AFM Notice on BlackRock Voting Rights - TradingView

QIAGEN N.V. (QIA) Discloses BlackRock 12.90% Voting Rights - TradingView

QIAGEN N.V. (QIA) Notes AFM Disclosure on BlackRock Voting Rights - TradingView

QIAGEN Expands AI-Powered Bioinformatics for Research and Drug Discovery - Business Wire

Global Microfluidics Market by Product Type, Application, End User, and Region, 2026-2036 | $48.04 Billion Opportunity Driven by Point-of-Care Diagnostics and Automation - GlobeNewswire Inc.

Europe Point of Care Diagnostics Market Size and Forecast, 2021 - 2031 | Market to Reach US$21.4 Billion by 2031 as Rapid Testing and Molecular Innovation Drive 13.4% CAGR - GlobeNewswire Inc.

Immunogenomics Market Size, Share, Trends, and Growth Forecast, 2026-2033 | NGS and Personalized Medicine Drive Market Toward USD 9.82 Billion at 5.97% CAGR - GlobeNewswire Inc.

Magnetic Beads Market - Global Forecast and Growth Opportunities, 2026-2032 | Automation, Genomics, and Molecular Diagnostics Drive 7.91% CAGR Toward USD 6.18 Billion - GlobeNewswire Inc.

Qiagen NV (CEUX:QIAD) Shiller PE Ratio : (As of Oct. 03, 2026) - GuruFocus

QIAGEN N.V. (QIA): Bank of America Holds 4.95% Voting Rights - TradingView

PTA-PVR: QIAGEN N.V.: Release according to Article 40, Section 1 of the WpHG - TradingView

QIAGEN N.V. (QIA) AFM Discloses Bank of America Voting Rights Notice - TradingView

Ähnlich wie QGEN

GRAL$143.439.75%

RDNT$73.490.22%

BLLN$113.321.32%

ICLR$211.361.91%

CDNA$87.4122.22%